 Connection
David Lynch to Pandemics
This is a "connection" page, showing publications David Lynch has written about Pandemics.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.405 |
|
|
|
-
Cha MJ, Solomon JJ, Lee JE, Choi H, Chae KJ, Lee KS, Lynch DA. Chronic Lung Injury after COVID-19 Pneumonia: Clinical, Radiologic, and Histopathologic Perspectives. Radiology. 2024 Jan; 310(1):e231643.
Score: 0.132
-
Avila RS, Fain SB, Hatt C, Armato SG, Mulshine JL, Gierada D, Silva M, Lynch DA, Hoffman EA, Ranallo FN, Mayo JR, Yankelevitz D, Estepar RSJ, Subramaniam R, Henschke CI, Guimaraes A, Sullivan DC. QIBA guidance: Computed tomography imaging for COVID-19 quantitative imaging applications. Clin Imaging. 2021 Sep; 77:151-157.
Score: 0.108
-
Medalia A, Lynch DA, Herlands T. Telehealth Conversion of Serious Mental Illness Recovery Services During the COVID-19 Crisis. Psychiatr Serv. 2020 08 01; 71(8):872.
Score: 0.104
-
Fern?ndez P?rez ER, Crooks JL, Lynch DA, Humphries SM, Koelsch TL, Swigris JJ, Solomon JJ, Mohning MP, Groshong SD, Fier K. Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety. Thorax. 2023 11; 78(11):1097-1104.
Score: 0.031
-
Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest IA, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perrella MA, Lynch DA, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg HJ, Rosas IO. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med. 2023 01; 11(1):87-96.
Score: 0.030
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|